SHANGHAI, March 2, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the Center for Drug Evaluation (CDE) of China's National...
Read More Details
Finally We wish PressBee provided you with enough information of ( CARsgen's Claudin18.2 CAR-T Therapy Satri-cel Granted Breakthrough Therapy Designation by the NMPA )
Also on site :
- Morning Report — Texas braces for more flood danger after Hill Country tragedy
- Bangladesh lawyers challenge ex-PM Hasina’s murder trial charges
- Ukraine plagued by ‘palace politics’ and purges – Economist